English
Bulgarian
Chinese (Simplified)
Croatian
Czech
Danish
Dutch
Finnish
French
German
Greek
Hebrew
Hindi
Indonesian
Italian
Japanese
Korean
Macedonian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swedish
Thai
Turkish
Vietnamese
Highlights from John Goldman Conference 2017: Carolina Pavlovsky
Highlights from the John Goldman Conference on CML 2017:
CML experts give their personal perspectives
In Spanish:
Perspectivas sobre nuevas estudios clínicos y cómo se transfieren al mundo real - especialmente en países en vía de desarollo
Dr Carolina Pavlovsky
FUNDALEU - Fundación para combatir la leucemia
Buenos Aires - Argentina
- Actualización del estudio CML-IV: Seguridad y eficacia de imatinib durante 10 años
- Actualización del estudio PACE: Uso de ponatinib en segunda y tercera línea
- Varios estudios clínicos del discontinuación del tratamiento y qué aspectos deberían considerarse en la aplicación práctica
- Tratamiento de la población pediátrica y el uso de nuevas tecnologías para el monitoreo molecular
Keynote Presentations iCMLf Prizes 2017
Keynote presentations from the recipients of the 2017 iCMLf Prizes
At the 19th Annual John Goldman Conference on CML in Estoril the iCMLf Directors awarded the Foundation’s 2017 prize medals. This was followed by keynote presentations from the three prize winners. You can view web streams of the keynote presentations here.
- 2017 Goldman Prize: Professor Timothy Hughes
- 2017 iCMLf Prize: Professor Jerald Radich
- 2017 Rowley Prize: Professor Tessa Holyoake
At Tessa’s request, her keynote was presented by Mhairi Copland, Professor of Translational Haematology at the Paul O’ Gorman Leukemia Research Center at the University of Glasgow.
Highlights from John Goldman Conference 2017: Prof. Jorge Cortes
Highlights from the John Goldman Conference on CML 2017:
CML experts give their personal perspectives
Perspectives on biology and clinical aspects
from Professor Jorge Cortes
MD Anderson Cancer Center
University of Texas, Houston (USA)
- Leukemic stem cells and microenvironment
- Biomarkers
- Conceptual understanding of treatment-free remission
- Treatment discontinuation with 2nd generation TKI's
- Update on the new ELN recommendations
- Patient-reported outcomes
- New modalities of monitoring patients
- Long-term outcomes from various clinical studies
EHA Highlights 2017: Prof. Jerry Radich
Perspectives on CML management
from Professor Jerry Radich
Fred Hutchinson Cancer Research Center
Seattle, USA
- Assessment of existing therapies in CML including new data on bosunitib in front-line therapy
- Emerging new therapies for CML and how they could come into practice
- Perspectives on treatment discontinuation
- Challenges of CML management in the emerging economic regions: access to treatment and testing
EHA Highlights 2017: Prof. Timothy Hughes
Highlights from EHA 2017:
2 CML experts give their personal perspectives
Perspectives on new CML studies from
Professor Timothy Hughes
South Australian Health and Medical Research Institute (SAHMRI), University of Adelaide, Royal Adelaide Hospital, Australia
- Phase II study on dasatinib in children and adolescents with CML-CP
- 10-year survival results of the German CML IV Study
- Year 2 results from the British Destiny Study
- Initial results from the Before trial: Bosutinib vs. Imatinib in newly diagnosed CML
- Update on treatment-free remission studies
ASH Highlights 2016: Associate Prof. Branford
Highlights from ASH 2016:
3 CML experts give their personal perspectives
This independent educational resource is supported by a grant from Novartis Oncology
Perspectives on molecular monitoring in CML from
Associate Professor Susan Branford, PhD
Center for Cancer Biology
SA Pathology, Adelaide, Australia
- Treatment-free remission studies including an update of the EURO-SKI trial
- New data on optimal timing for monitoring patients after stopping therapy
- Additional chromosomal abnormalities and their impact on prognosis
- Next generation sequencing technologies
